A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant
Phase of Trial: Phase I/II
Latest Information Update: 15 Aug 2017
At a glance
- Drugs Sapanisertib (Primary) ; Exemestane; Fulvestrant
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 08 Aug 2017 Planned End Date changed from 12 Nov 2017 to 16 Mar 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 31 Jan 2018.
- 20 Apr 2017 Planned End Date changed from 1 Nov 2017 to 12 Nov 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History